抗繆勒氏荷爾蒙與婦科腫瘤的檢視

Anti-Mullerian Hormone and Gynecologic Cancer

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 沈仁達(Jenta Shen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2009年2期 (2009/10) Pp. 24-27

https://doi.org/10.7010/JGO.200910.0024

摘要

抗繆勒氏荷爾蒙又名繆勒氏抑制物質，主要功能在抑制男性胚胎繆勒氏管的發育，促成男性內生殖器官的發育。女性胎兒因在胚胎期不產生抗繆勒氏荷爾蒙，故能發育出女性內生殖器，但到青春時，卵巢囊狀濾泡的顆粒細胞開始產生少量抗繆勒氏荷爾蒙，相信有調節濾泡的發育的功能。但在某些卵巢癌，特別是卵巢顆粒細胞腫瘤或Sertoli細胞腫瘤，可利用組織免疫染色和血清檢查，協助術前之診斷和術後之追蹤。

關鍵字

抗繆勒氏荷爾蒙 ； 顆粒細胞腫瘤 ； 卵巢性索基質瘤

並列摘要

Anti-mullerian hormone (AMH), also known as Mullerian inhibiting substance, is a key factor in embryonic sex differentiation in males. In postnatal females, AMH is secreted by the primary, secondary and antral follicles and appears to regulate early follicular development. Beside AMH inhibits mullerian duct development in the male fetus, it seems to have other functions in the ovary and may play a role in ovarian cancer. Several studies suggest that the measurement of mullerian inhibiting substance in serum may be used to early detect persistent or recurrent disease in patients with ovarian sex-cord tumors. In addition, immunoreaction of AMH expression in tumor cells helps to distinguish between granulosa or Sertoli cell tumors and other gonadal tumors of different origins.

並列關鍵字

Anti-mullerian hormone ； granulosa cell tumor ； ovarian sex-cord stromal tumor